For the recently completed fourth quarter, Merck booked an adjusted profit of $1.72 per share on $15.6 billion in revenue. Sales of top-selling cancer treatment Keytruda climbed 19% to $7.84 billion.

Merck & Co. (NYSE:MRK) is a prominent American multinational pharmaceutical company many investors know for its brand-name drugs such as Keytruda, and the myriad of commercials the company shows on ...

Shares of Merck slid Tuesday after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales forecast due partly to a pause in shipments of one of its top-selling products to China.

Merck achieved revenue growth in Q4, but stocks tumbled Tuesday amid news that the company is pausing Gardasil shipments to China. © 2024 Fortune Media IP Limited ...

Merck’s Q4 sales rose 7% YoY to $15.62B, slightly beating the $15.49B consensus. Adjusted EPS jumped to $1.72, topping estimates of $1.62. Keytruda sales grew 19% YoY to $7.84B, while Gardasil ...

West Point leaders complied with President Trump’s D.E.I. ban by ending a dozen student clubs. Critics say the move ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Merck shares tumbled after the drugmaker said it was halting shipments of a top-selling vaccine to China to ...

Merck (MRK) stock was mangled today after the pharmaceutical and vaccine company released its guidance for 2025. The company expects adjusted earnings per share for the year to range from $8.88 to ...

The pause announcement comes a month after Merck received approval in China for use of the vaccine in males. “We believe China still represents a significant, long-term opportunity for Gardasil ...

The military academy ordered the closure of a dozen clubs for students affiliated with its Diversity, Equity and Inclusion ...

Copyright 2025 The Associated Press. All Rights Reserved. A Merck scientist conducts research on Feb. 28, 2013, in West Point, Pa. (AP Photo/Matt Rourke, File ...